Amivantamab in Recurrent/Metastatic Head and Neck Squamous Cell Cancer After Checkpoint Inhibitor and Chemotherapy: Pivotal Results From the Phase Ib/II OrigAMI-4 Study

The phase Ib/II OrigAMI-4 study reports pivotal results for amivantamab, a bispecific EGFR-MET antibody, in patients with recurrent or metastatic head and neck squamous cell carcinoma who progressed after checkpoint inhibitor therapy and chemotherapy. This represents a heavily pretreated population with limited therapeutic options, and the study was published in the Journal of Clinical Oncology (Vol. 44, August 2026). While specific efficacy data are not available from the abstract alone, the designation as pivotal results suggests clinically meaningful activity warranting further development in this indication.